$AVR

Knight Susan Elizabeth purchased $102K of AVR

Knight Susan Elizabeth purchased 11,000 shares of Anteris Technologies Global Corp. (AVR) at $9.29 ($0.10M total) on 2026-06-02.

Original reporting
SEC EDGAR · Knight Susan Elizabeth
Published Jun 4, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVR
Bullish
medium confidence
Mentioned
$AVR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRBullishLow
01

Why it matters

The transaction may be interpreted as confidence in the stock, but it does not change fundamentals on its own without additional company-specific news.

02

Market read

Traders may use the buy as a small sentiment input, but it is unlikely to be a standalone driver of price action.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no context on prior holdings, motivation, or whether other insiders are buying/selling.

Relevance 6/10Novelty 6/10Timing: Filed after-hours on 2026-06-04; reflects purchase dated 2026-06-02.

Background

The article is an SEC Form 4 disclosure of an insider’s open-market purchase by a director.

Company-level read

Ticker impact

$AVRBullishMedium confidence
Context

Director Susan Elizabeth Knight bought 11,000 shares of Anteris Technologies Global Corp. at $9.2935/share via open-market purchase.

Expected impact

Likely limited/short-lived price impact; may slightly improve near-term sentiment rather than drive a trend.

Evidence & confidence

The filing is a Form 4 insider transaction with a disclosed buy price and size, but no accompanying corporate event (earnings, guidance, deal, or regulatory action) is mentioned.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (e.g., diversification, compensation-related liquidity) and may not signal near-term upside.

Key entities

  • Anteris Technologies Global Corp.

    Subject of the Form 4 insider purchase disclosure (AVR).

  • Susan Elizabeth Knight

    Director who purchased 11,000 shares on 2026-06-02.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.